CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy

CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy

CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy
RestartResume

Learn about the CARE HK study to explore real-world factors that influence RAASi treatment decisions in HF patients with or at risk for hyperkalemia.

  • Overview

    Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world data surrounding this question and its associated impact on outcomes.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free